Literature DB >> 27287331

Leukocyte Profile in Peripheral Blood and Neutrophil-Lymphocyte Ratio in Hidradenitis Suppurativa: A Comparative Cross-Sectional Study of 462 Cases.

Iben Marie Miller1, Hans Christian Ring, Errol P Prens, Helene Rytgaard, Ulla B Mogensen, Christina Ellervik, Gregor B E Jemec.   

Abstract

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease. Increasing evidence suggests that HS involves dysfunctional immune responses in both the adaptive and the innate immune system. The recently proposed association of HS with metabolic syndrome may further add to the inflammatory state in HS.
OBJECTIVE: To investigate the status of inflammation and leukocyte profile in the peripheral blood of HS patients.
MATERIALS AND METHODS: Using a comparative cross-sectional study design, we investigated blood samples of high-sensitivity C-reactive protein (hs-CRP) and leukocyte profile in hospital-treated HS patients (HS-HOSP), self-reported population-based HS patients (HS-POP) and population controls.
RESULTS: Our study comprised 32 individuals in the HS-HOSP group, 430 in the HS-POP group, and 20,780 controls. The median hs-CRP for the HS-HOSP group was 5.1 mg/l (quartile range 2.6-8.2), 2.2 mg/l (1.0-4.3) for the HS-POP group and 1.3 mg/l (0.7-2.9) for the controls. An age-sex-adjusted analysis revealed a significantly higher hs-CRP for both HS groups compared to controls (p < 0.0001). When performing age-sex-adjusted analysis, both HS groups had significantly higher odds of leukocytosis when compared to controls with an odds ratio for the HS-HOSP group of 4.38 (95% CI = 2.18-8.80; p < 0.0001) and 1.95 (95% CI = 1.58-2.42; p < 0.0001) for the HS-POP group. The age-sex-adjusted leukocyte differential count yielded significantly higher neutrophil (p < 0.0001) and monocyte (p = 0.0014, p = 0.0004) levels in the HS groups compared with controls.
CONCLUSION: The hs-CRP levels associated with HS appear to be intermediate (2.2-5.1 mg/l), implying systemic inflammation rather than infection. The peripheral blood leukocytosis in HS was dominated by neutrophils and monocytes.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27287331     DOI: 10.1159/000446021

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  6 in total

1.  Treatment of hidradenitis suppurativa resolves associated hematologic abnormalities.

Authors:  Peyton C Morss-Walton; Charlotte Greif; Zachary E Holcomb; Prerna Salian; Tuyen Yankama; Diana Kim; Martina L Porter; Alexa B Kimball
Journal:  Int J Womens Dermatol       Date:  2022-03-25

2.  What's Race Got to Do With It? CRP Levels in Immune Mediated Skin Diseases: Considerations for Hidradenitis Suppurativa.

Authors:  Chidubem A V Okeke; Jonathan P Williams; Callyn U Iwuala; Pearl K Igwe; Raveena Khanna; Jessica D Perry; Ginette A Okoye; Angel S Byrd
Journal:  Front Immunol       Date:  2022-03-29       Impact factor: 7.561

3.  Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa.

Authors:  Kevin T Savage; Elena Gonzalez Brant; Monica Rosales Santillan; Peyton C Morss; Prerna Salian; Kelsey S Flood; Martina L Porter; Alexa B Kimball
Journal:  Int J Womens Dermatol       Date:  2020-02-25

4.  Evaluation of Serum Adenosine Deaminase and Inflammatory Markers in Psoriatic Patients.

Authors:  Yousry M Moustafa; Moustafa Ahmed Elsaied; Ehsan M Abd-Elaaty; Rasha A Elsayed
Journal:  Indian J Dermatol       Date:  2019 May-Jun       Impact factor: 1.494

5.  Hidradenitis suppurativa in acute myeloid leukemia: Review of disease course and management.

Authors:  Stella X Chen; Christina G Lopez; Bina Kassamali; Marlise R Luskin; Alexandra Charrow
Journal:  JAAD Case Rep       Date:  2021-11-24

Review 6.  Hidradenitis Suppurativa and 1-Carbon Metabolism: Role of Gut Microbiome, Matrix Metalloproteinases, and Hyperhomocysteinemia.

Authors:  Jack Molnar; Carissa Jo Mallonee; Dragana Stanisic; Rubens P Homme; Akash K George; Mahavir Singh; Suresh C Tyagi
Journal:  Front Immunol       Date:  2020-08-19       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.